

DEPARTMENT OF HEALTH AND HUMAN SERVICES
ADVANCED AGREEMENT BETWEEN THE ASSISTANT SECRETARY FOR
PREPAREDNESS AND RESPONSE (ASPR), BIOMEDICAL ADVANCED RESEARCH
AND DEVELOPMENT AUTHORITY (BARDA)

AND
ASTRAZENECA

OTHER TRANSACTION AGREEMENT NUMBER: 75A501-20-C-00114 MOD P00001
TITLE FOR: ChAdOx1nCoV-19 Vaccine Clinical Development and Manufacturing

The purpose of this modification is to (b)(4) of the Other
Transaction Agreement (OTA)

Modification of subject Advanced Agreement to be as follows:

FROM:

(b)(4)



This instrument has been negotiated pursuant to Section 247d-7e (c)(4)(B) of Title 42 U.S. Code

There are no other changes to Terms and Conditions of this Agreement

(b)(6)



Ruud Dobber, PhD
EVP and President,
BioPharmaceuticals Business Unit
AstraZeneca Pharmaceuticals LP
1800 Concord Pike
Wilmington, DE 19803

Handwritten signature of Francine Hemphill in black ink.

07/31/2010

Francine Hemphill
Other Transaction Agreement's Officer

July 31, 2020

(Date)